

# RED LIGHT, GREEN LIGHT WHAT ABOUT THE YELLOW LIGHT?

## Exploring the complexities of treatment TOLERABILITY IN FABRY DISEASE

Presenters will explore the mechanisms, immunogenicity, and patient-specific factors that influence the tolerability of enzyme replacement therapies (ERTs) in Fabry disease.

This symposium will discuss pegunigalsidase alfa tolerability data and highlight future directions toward enhancing patient outcomes. The presentation will include case studies and a panel discussion with speakers, concluding with a Q&A session.

**JOIN US ON  
WEDNESDAY,  
FEBRUARY 5, 2025  
12:15 pm – 1:15 pm PDT**

**📍 Manchester Grand Hyatt  
San Diego, CA, USA  
Grand Hall AB**

## SPEAKERS



### **Uma Ramaswami, MD**

Consultant in Inherited Metabolic Disorders,  
Royal Free London Hospital,  
Genetics and Genomics Medicine,  
University College London,  
London, UK



### **Christina Lampe, MD**

Director of the Centre for Rare Diseases,  
Department of Pediatric Neurology, Muscular Diseases, and Social Pediatrics,  
University of Giessen,  
Giessen, Germany



### **Robert Hopkin, MD**

Professor of Clinical Pediatrics,  
Cincinnati Children's Hospital Medical Center,  
Cincinnati, OH, USA

**This session is sponsored by Chiesi Global Rare Diseases.  
This is not a continuing education (CE) activity.**

This Satellite Symposium is not part of the official *WORLDSymposium™* program, and *WORLDSymposium* does not approve or endorse any commercial products or services discussed during the Satellite Symposium or offered for sale by the corporate supporter of the Satellite Symposium. This Satellite Symposium is not approved for CE by *WORLDSymposium* or any other entity.

Eligibility: Registration for *WORLDSymposium 2025* and an official name badge are required to attend this Satellite Symposium.

GRDMA-US-EF-00898

